ID

16688

Description

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Study Drug Administration

Lien

https://clinicaltrials.gov/ct2/show/NCT00373425

Mots-clés

Versions (2)
  1. 27/07/2016 27/07/2016 -
  2. 01/08/2016 01/08/2016 -
Téléchargé le

1 août 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Anglais

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulaires  
Study Drug Administration
Description

Study Drug Administration

Start Date
Description

Study Drug Administration Start Date

Type de données

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0808070
Administered Dose
Description

Dose

Type de données

float

Unités de mesure
  • mg
Alias
UMLS CUI [1]
C0178602
mg
Stop Date
Description

Study Drug Administration Stop Date

Type de données

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
Dose Modification
Description

Record toxicities on the Adverse Events page.

Type de données

integer

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C0392360
If other, specify:
Description

Other Dose Modification Reason

Type de données

text

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C3840932
Missed Doses
Description

Record the number of missed doses, if any, for the time between the start and stop dates.

Type de données

integer

Alias
UMLS CUI [1,1]
C1709043
UMLS CUI [1,2]
C0750480
Retour au début de la page

Similar models

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Study Drug Administration
Study Drug Administration Start Date
Item
Start Date
date
C0013227 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Dose
Item
Administered Dose
float
C0178602 (UMLS CUI [1])
Study Drug Administration Stop Date
Item
Stop Date
date
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Dose Modification
integer
C1707811 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Study Drug Dose Modification
Code List
Dose Modification
CL Item
Drug-related Toxicity (AE) (1)
CL Item
Nondrug-related Toxicity (AE) (2)
CL Item
Patient Request  (3)
CL Item
Toxicity lmproved  (4)
CL Item
No Modification (5)
CL Item
Other (specify) (6)
Other Dose Modification Reason
Item
If other, specify:
text
C1707811 (UMLS CUI [1,1])
C3840932 (UMLS CUI [1,2])
Missed Doses
Item
Missed Doses
integer
C1709043 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial